Health Care Technology
Company Overview of Definiens AG
Definiens AG provides biomedical image analysis and data mining software solutions for life sciences, tissue diagnostics, and clinical digital pathology markets. It offers Definiens Tissue Studio, a solution for biomarker and morphological profiling in research and drug discovery on tissue samples, as well as detects regions of interest and distinguishes cell types and cell subtypes within target regions across various tissue slides; and Definiens Developer XD, a solution for scientists and image analysis experts to create and validate automated solutions for a range of biomedical image analysis problems. The company also provides Definiens Image Miner, a solution that integrates data mining...
Founded in 1994
Key Executives for Definiens AG
Founder, Chief Technology Officer and Director
Compensation as of Fiscal Year 2017.
Definiens AG Key Developments
Definiens Announces Executive Changes
Jul 24 17
Definiens announced the strengthening of its leadership team. To support the company’s strategic expansion Definiens appointed Dr. Heinz Oehl as VP of Global Marketing & Corporate Business Development. In addition, Michael Rasche, formerly Global Head of Sales and Business Development, has been promoted to Chief Commercial Officer (CCO). Dr. Heinz Oehl is an MD with more than 15 years of experience in the healthcare and life science industries. With Michael Rasche’s leadership Definiens has experienced significant business growth in oncology and immuno-oncology partnerships with the most relevant I/O Pharma and Biotech companies.
NeoGenomics, Inc. and Definiens Enter into Agreement to Develop Novel Assays for Clinical Trials and Clinical Testing
Mar 13 17
NeoGenomics, Inc. and Definiens announced that they have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing. Under the agreement, Definiens will provide automated quantitative biomarker solutions to support NeoGenomics' immunohistochemistry services for both its Pharma Services customers and Clinical clients, helping to improve pathology interpretation, standardize the readout (analysis/scoring), and identify the signature for optimal biomarker cut point threshold. NeoGenomics excels in providing custom developed Immunohistochemistry (IHC) assays to be used in clinical trials, companion diagnostics and clinical testing. Automated IHC workflows, quantification, and interpretation tools remove variability of pathology scoring criteria and will allow researchers and pathologists a higher level of analytical consistency to standardize biomarker analysis for global clinical trials and clinical testing.
Definiens Expands Boston-Based Office in Response to Growth in U.S. Market
Aug 30 16
Definiens announced that it is expanding its presence in the U.S. to meet growing customer needs. The company opened its Boston office last year, and since then has experienced significant growth in providing tissue-based services to pharmaceutical companies, academic medical centers, comprehensive cancer centers and biotech companies in North America, prompting further expansion in the market. The office, based just outside Boston in Cambridge, MA, will become the company’s new U.S. headquarters. The company will continue to focus on enhancing its offerings for customers, and as part of that will be recruiting additional technical engineering employees as well as commercial leaders for the Boston office.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|